1. "2013"
  2. "Thoracic Oncology"
Formats
  1. Meeting Abstract (65)
  2. Journal Article (29)
Groups
  1. Department of Medicine (94)
  2. Solid Tumor Oncology Division (94)
  3. Thoracic Oncology (94)
  4. GSK Faculty (38)
  5. Human Oncology and Pathogenesis Program (33)
  6. Tow Center for Developmental Oncology (TCDO) (32)

More Groups

People
  1. Mark Kris (46)
  2. Gregory Riely (45)
  3. Marc Ladanyi (30)
  4. Camelia Sima (23)
  5. Jamie Chaft (18)
  6. Lee Krug (14)

More People

Years
  1. 2013 (94)
Publications
  1. Journal of Thoracic Oncology (34)
  2. Journal of Clinical Oncology (18)
  3. Modern Pathology (4)
  4. Annals of Oncology (3)
  5. Clinical Cancer Research (3)
  6. International Journal of Radiation Oncology, Biology, Physics (3)

More Publications

Publishers
  1. Elsevier Inc. (39)
  2. American Society of Clinical Oncology (18)
  3. American Association for Cancer Research (7)
  4. Oxford University Press (5)
  5. Nature Publishing Group (4)
  6. Nature Research (4)

More Publishers

Results (94)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparison of the characteristics and clinical course of 677 patients with metastatic lung cancers with mutations in KRAS codons 12 and 13
    Meeting Abstract

    Yu, H. A.; Sima, C. S.; Shen, R. L.; Kass, S. L.; Kris, M. G.; Ladanyi, M.; Riely, G. J.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Solomon, B. J.; Gettinger, S. N.; Riely, G. J.; Gadgeel, S. M.; Nokihara, H.; Han, J. Y.; Hida, T.; Satouchi, M.; Baldini, E.; Siena, S.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Response to erlotinib and prognosis for patients with de novo epidermal growth factor receptor (EGFR) T790M mutations
    Meeting Abstract

    Riely, G. J.; Yu, H. A.; Arcila, M. E.; Hellmann, M. D.; Ladanyi, M.; Kris, M. G.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients
    Meeting Abstract

    Planchard, D.; Mazieres, J.; Riely, G. J.; Rudin, C. M.; Barlesi, F.; Quoix, E. A.; Souquet, P. J.; Socinski, M. A.; Switzky, J.; Ma, B.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Patterns of metastasis and survival in patients with PI3K pathway-driven stage IV squamous cell lung cancers (SQCLC)
    Meeting Abstract

    Paik, P. K.; Moreira, A. L.; Wang, L.; Won, H. H.; Hasanovic, A.; Rekhtman, N.; Sima, C. S.; Ladanyi, M.; Berger, M. F.; Kris, M. G.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Ou, S. H. I.; Bang, Y. J.; Camidge, D. R.; Riely, G. J.; Salgia, R.; Shapiro, G.; Solomon, B. J.; Engelman, J. A.; Kwak, E. L.; Clark, J. W.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Incidence, characteristics, and survival of patients with EGFR-mutant lung cancers with EGFR T790M at diagnosis identified in the lung cancer mutation consortium (LCMC)
    Meeting Abstract

    Kris, M. G.; Oxnard, G. R.; Johnson, B. E.; Berry, L. D.; Chen, H.; Kwiatkowski, D. J.; Iafrate, A. J.; Wistuba, I. I.; Franklin, W. A.; Aisner, D.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Feasibility of long-term patient reporting of toxicities from home via the internet during routine chemotherapy
    Meeting Abstract

    Judson, T. J.; Bennett, A. V.; Rogak, L. J.; Sit, L.; Barz, A.; Kris, M. G.; Hudis, C.; Scher, H. I.; Sabbatini, P.; Schrag, D.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs)
    Meeting Abstract

    Johnson, M. L.; Hart, E. M.; Rademaker, A.; Weitner, B. B.; Urman, A.; Simm, H. D.; Fountas, L. M.; Worden, R.; Patel, J. D.; Miller, V. A.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC)
    Meeting Abstract

    Johnson, B. E.; Kris, M. G.; Berry, L. D.; Kwiatkowski, D. J.; Iafrate, A. J.; Varella-Garcia, M.; Wistuba, I. I.; Franklin, W. A.; Ladanyi, M.; Su, P. F.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save